ArticleHuman vaccines & immunotherapeutics2020
Prevalence, genotype distribution and risk factors of cervical HPV infection in Yangqu, China: a population-based survey of 10086 women.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Association BetweenFrontiers in genetics · 2022Pooled it
- Comparison of mRNA-based and next-generation sequencing HPV assays in a population-based cervical cancer screening program in China.Journal of gynecologic oncology · 2026Article
- Informative High-Risk HPV Genotyping in Cervical Cancer Screening: Integrated Analysis of Cytology and p16/Ki67 Dual Staining.Cancers · 2026Article
- Genotype distribution and risk factors for human papillomavirus infection.Journal of gynecologic oncology · 2026Article
- Urinary detection of high-risk HPV DNA to enhance cervical cancer screening in developing countries.Microbiology spectrum · 2025Article
- Human Papillomavirus in Jordan-A selective study of 650 cases.IJID regions · 2025Article
- Prevalence of HPV infection and cervical lesions among women with pelvic organ prolapse and implications for preoperative evaluation.BMC cancer · 2025Article
- Article
- Multicenter study on the distribution and prevalence of human papillomavirus types in Hangzhou, Zhejiang from 2017 to 2023.Scientific reports · 2025Article
- Influence of COVID-19 pandemic on prevalence and genotype distribution of HPV in cervical cancer screening population.Virology journal · 2024Article
- Distribution of HPV genotypes in Mashhad, Iran: insights from a 2022-2023 study.Virology journal · 2024Article
- Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross-sectional study based on post-vaccination period 2019 to 2023.Cancer medicine · 2024Article
- Prevalence of HPV Genotypes among Greek Women in Association with Their Potential to Cause Precancerous Lesions.Microorganisms · 2024Article
- Prevalence characteristics of cervical human papillomavirus infection in Chengdu and Aba District, Sichuan Province, China.PloS one · 2024Article
- Analysis of the correlation between cervical HPV infection, cervical lesions and vaginal microecology.Frontiers in cellular and infection microbiology · 2024Article
- The interplay between programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) genotypes in cervical carcinomas: findings of a Nigerian Tertiary Hospital.The Pan African medical journal · 2024Article
- Epidemiology and genotypes analysis of human papillomavirus infection in Huizhou, China.Frontiers in public health · 2024Article
- Prevalence and sociodemographic predictors of high-risk vaginal human papillomavirus infection: findings from a public cervical cancer screening registry.BMC public health · 2023Article
- Independent risk factors for high-risk human papillomavirus infection among rural women in Shanxi Province, China: a population-based, case-control study.Archives of gynecology and obstetrics · 2023Article
- Prevalence and genotype distribution of human papillomavirus infections in Beijing, China between 2016 and 2020.Virology journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus(HPV) infection is a necessary factor for the development of cervical cancer. The HPV vaccine is currently available, but there is still a lack of large-scale research on the distribution and risk factors of HPV. The aim of this study is to investigate the genotype distribution and risk factors of HPV infection in Yangqu which is located in North China. This study enrolled 10086 women aged <65 years from Yangqu County. HPV genotypes were identified via standard HPV DNA testing. The overall prevalence of HPV infection was 8.92%. The prevalence of high-risk HPV types was 8.80%, and it was 0.38% for low-risk HPV types. Single genotype infection accounted for 67.91% in HPV-positive cases. The most common HPV genotypes were HPV-16, -52, and -58. HPV-18 was only the 11th most common type in HPV-positive cases. Women ≥50 years of age had the highest prevalence rate of HPV, and women <30 years had the lowest prevalence rate. The distribution of HPV genotypes also varied among the three age groups: <30, 30-49, and ≥50 years. The risk factors that contributed to the rate of HPV infection included low educational level, low income, smoking, age at first sexual encounter <23 years old, and number of births ≥3 times. This large routine clinical practice report of HPV prevalence and genotype distribution revealed the characteristics of HPV infection-type distributions in Shanxi Province, which should be considered in formulating comprehensive prevention strategies including vaccination for cervical cancer in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.